Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Cabozantinib in combination with nivolumab for previously untreated advanced renal cell cancer

5 October 2026

Condition

Cancer

Kidney

Published on 31 Aug 2022
Last Updated on 05 Oct 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended cabozantinib in combination with nivolumab for inclusion on the MOH List of Subsidised Drugs for previously untreated advanced renal cell cancer in view of unfavourable cost-effectiveness compared with alternative treatments.

Clinical indications, subsidy class and MediShield Life claims eligibility for both drugs are provided in the Annex.

Cabozantinib in combination with nivolumab for previously untreated advanced renal cell cancer (Updated 05 Oct 2026) [PDF, 205.17 KB] (opens in new tab)

PES Treatments for advanced renal cell carcinoma (Updated 2 Jan 2024) [PDF, 111 KB] (opens in new tab)